FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

UK Banks Reject Opportunity to Lift £100 Contactless Limit

Major UK banks choose not to increase contactless payment thresholds.Highlights: UK banks will not raise the £100 contactless...
FinTech

Crypto.com Cuts 12% of Workforce Amid AI Shift

The company streamlines operations in response to evolving market dynamics.Highlights: Crypto.com reduces workforce by 12%Focus shifts to AI...
FinTech

Tide Strengthens Leadership with PPRO CTO Appointment

The fintech company welcomes a new chief technology officer to enhance its team.Highlights: Tide appoints ex-PPRO CTO to...
FinTech

Visa Overcomes Legacy Issues with Unified API for Intelligent Authorization

New API aims to streamline payment processes and enhance security features.Highlights: Visa launches a unified API to improve...